The AGGF1 Knockout KYSE-150 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the AGGF1 gene in a human esophageal squamous cell carcinoma background. This loss-of-function model is generated in the KYSE-150 host cell line and is provided as a polyclonal pool, enabling gene perturbation studies without the need for single-cell clone selection. Homo sapiens-derived, this product serves as a versatile tool for examining AGGF1-dependent cellular processes.
The host cell line KYSE-150 is an adherent, poorly differentiated esophageal squamous cell carcinoma line originally established from a 49-year-old female patient. KYSE-150 is widely employed in cancer biology research, particularly for investigating molecular mechanisms of esophageal squamous cell carcinoma tumorigenesis, metastasis, and drug response. Its well-characterized growth properties and genetic background make it a suitable chassis for CRISPR/Cas9-mediated gene disruption.
AGGF1 encodes a secreted angiogenic factor critical for vascular development. It binds to FN14 (TNFRSF12A) and integrin ??9??1, activating PI3K-AKT and ERK signaling pathways to promote endothelial cell proliferation, migration, and tube formation. Representative pathway components include AGGF1, FN14, AKT, ERK, eNOS, and VEGF. AGGF1 expression is upregulated by angiogenic stimuli such as hypoxia and growth factors, coupling environmental cues to endothelial cell activation and neovascularization.
In the KYSE-150 context, AGGF1 knockout provides a relevant model to interrogate the contribution of angiogenic signaling to esophageal squamous cell carcinoma progression. Since AGGF1 is implicated in promoting angiogenesis, its disruption in tumor-derived cells allows researchers to dissect autocrine and paracrine effects on endothelial cell crosstalk, tumor microenvironment remodeling, and potential resistance to anti-angiogenic therapies. This polyclonal knockout cell population is particularly suited for studies where heterogeneous gene editing mimics physiological variability.
Key research applications include investigations of angiogenesis mechanisms, Klippel-Trenaunay syndrome pathogenesis, and cancer-associated vascular biology. Typical assays employ western blotting to assess AGGF1 protein levels and phosphorylation status of AKT and ERK, tube formation assays for angiogenic capacity, and cell proliferation and migration experiments. Advanced applications encompass RNA-seq transcriptomics and immunofluorescence staining for endothelial markers. For further details and pricing, please contact Ascent Research.
